DARA BioSciences Observes National Neuropathy Awareness Week

DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care specialty
pharmaceutical company dedicated to providing healthcare professionals a
synergistic portfolio of medicines to help cancer patients adhere to their
therapy and manage side effects arising from their cancer treatments, announced
its support for Neuropathy Awareness Week which is being observed during the
week of May 12, 2014 and sponsored in the U.S. by The Neuropathy Association
(www.neuropathy.org).


"We support The Neuropathy Association in its mission to help and heal people
with peripheral neuropathy," said David J. Drutz, M.D., Chief Executive Officer
and Chief Medical Officer of DARA BioSciences. "As a member of The North
Carolina Biosciences Organization (NCBIO), which is the trade association for
North Carolina's life science community, we were able to sponsor a proclamation
in North Carolina in support of Neuropathy Awareness Week signed by Governor Pat
McCrory. We are proud to support groups like the Neuropathy Association which
provide neuropathy awareness, education, support, advocacy and research to the
public and health care providers." 


Peripheral neuropathy is a disorder of the peripheral nerves -- the motor,
sensory and autonomic nerves that connect the spinal cord to muscles, skin and
internal organs. It usually affects the hands and feet, causing weakness,
numbness, tingling and pain. Peripheral neuropathy's course is variable; it can
come and go, slowly progressing over many years, or it can become severe and
debilitating. However, if diagnosed early, peripheral neuropathy can often be
controlled. 


Peripheral neuropathy is common. It is estimated that upwards of 20 million
Americans suffer from this illness. It can occur at any age, but is more common
among older adults. Approximately 8 - 9 percent of Medicare recipients have
peripheral neuropathy as their primary or secondary diagnosis, according to a
1999 survey. The annual cost to Medicare exceeds $3.5 billion. 


Peripheral neuropathy has always been present, but has not received much
attention. Its extent and importance have not yet been adequately recognized. It
is apt to be misdiagnosed, or thought to be merely a side effect of another
disease like diabetes or cancer or kidney failure. The development of new
therapies has unfortunately been slow and underfunded. 


Earlier this year, the U.S. Food and Drug Administration (FDA) granted Orphan
Drug Designation to DARA's KRN5500, a novel, non-opioid, non-narcotic
intravenous product currently in Phase 2 clinical development for the parenteral
treatment of painful, chronic, chemotherapy-induced peripheral neuropathy
(CCIPN) that is refractory to conventional analgesics. 


About DARA BioSciences, Inc. 

DARA BioSciences Inc. of Raleigh, North Carolina, is an oncology supportive care
pharmaceutical company dedicated to providing healthcare professionals a
synergistic portfolio of medicines to help cancer patients adhere to their
therapy and manage side effects arising from their cancer treatments. 


DARA holds exclusive U.S. marketing rights to both Soltamox® (tamoxifen
citrate) oral solution and Gelclair®. DARA licensed the U.S. rights to
Soltamox® from UK-based Rosemont Pharmaceuticals, Ltd., and Gelclair® from the
Helsinn Group in Switzerland. Under an agreement with Innocutis, DARA also
markets Bionect® (hyaluronic acid sodium salt, 0.2%).  


Soltamox® (tamoxifen citrate) oral solution, the only liquid form of tamoxifen,
is indicated for the treatment of metastatic breast cancer, the adjuvant
treatment of node-positive breast cancer in postmenopausal women, the reduction
in risk of invasive breast cancer in women with ductal carcinoma in situ (DCIS),
and for the reduction of the incidence of breast cancer in women at high risk
for breast cancer. Currently, there are more than 1.8 million prescriptions of
tamoxifen written on an annual basis in the United States. Between 30 and 70
percent of patients fail to complete their prescribed course of treatment,
thereby diminishing its benefits in reducing the risk of breast cancer
recurrence.  


Tamoxifen Important Safety Information 

Tamoxifen citrate is contraindicated in women who require concomitant
coumadin-type anticoagulant therapy, in women with a history of deep vein
thrombosis or pulmonary embolus, and in women with known hypersensitivity to the
drug or any of its ingredients. 


Serious and life-threatening events associated with tamoxifen in the risk
reduction setting (women at high risk for cancer and women with DCIS) include
uterine malignancies, stroke and pulmonary embolism. 


The most common adverse reactions to tamoxifen treatment are (incidence >
20%) hot flashes, fluid retention, vaginal discharge, vaginal bleeding,
vasodilatation, nausea, irregular menses, weight loss, and musculoskeletal
events. 


Tamoxifen carries the following Boxed Warning:  

WARNING -- For Women with Ductal Carcinoma in Situ (DCIS) and Women at High Risk
for Breast Cancer: Serious and life-threatening events associated with tamoxifen
in the risk reduction setting (women at high risk for cancer and women with
DCIS) include uterine malignancies, stroke and pulmonary embolism. Incidence
rates for these events were estimated from the NSABP P-1 trial (see CLINICAL
PHARMACOLOGY, Clinical Studies, Reduction in Breast Cancer Incidence In High
Risk Women). Uterine malignancies consist of both endometrial adenocarcinoma
(incidence rate per 1,000 women-years of 2.20 for tamoxifen vs. 0.71 for
placebo) and uterine sarcoma (incidence rate per 1,000 women-years of 0.17 for
tamoxifen vs. 0.0 for placebo)*. For stroke, the incidence rate per 1,000
women-years was 1.43 for tamoxifen vs. 1.00 for placebo**. For pulmonary
embolism, the incidence rate per 1,000 women-years was 0.75 for tamoxifen versus
0.25 for placebo**. Some of the strokes, pulmonary emboli, and uterine
malignancies were fatal. Health care providers should discuss the potential
benefits versus the potential risks of these serious events with women at high
risk of breast cancer and women with DCIS considering tamoxifen to reduce their
risk of developing breast cancer. The benefits of tamoxifen outweigh its risks
in women already diagnosed with breast cancer. 


*Updated long-term follow-up data (median length of follow-up is 6.9 years) from
NSABP P-1 study. See WARNINGS, Effects on the Uterus-Endometrial Cancer and
Uterine Sarcoma in Prescribing Information. **See Table 3 under CLINICAL
PHARMACOLOGY, Clinical Studies in Prescribing Information.


The full Prescribing Information for Soltamox is available at
www.soltamox.com/prescribing-information. 


Gelclair® is an alcohol-free bioadherent oral rinse gel for rapid and effective
relief of pain associated with oral mucositis caused by chemotherapy and
radiation treatment. Gelclair should not be used by patients with a known or
suspected hypersensitivity to the product or any of its ingredients. DARA
licensed the U.S. rights to Soltamox from UK-based Rosemont Pharmaceuticals,
Ltd., and Gelclair from the Helsinn Group in Switzerland. Under an agreement
with Innocutis, DARA also markets Bionect® (hyaluronic acid sodium salt, 0.2%)
a topical treatment for skin irritation and burns associated with radiation
therapy, in U.S. oncology/radiology markets. Bionect should not be used by
patients with known hypersensitivity to any of its ingredients. For further
information on Gelclair and Bionect and the Full Prescribing Information please
visit www.Gelclair.com and www.Bionect.com. 


DARA is focused on expanding its portfolio of oncology supportive care products
in the United States, via in-licensing and/or partnering of complementary
late-stage and approved products. In addition, the company wishes to identify a
strategic partner for the clinical development of KRN5500, currently in Phase 2
for the treatment of chronic, treatment refractory, chemotherapy-induced
peripheral neuropathy (CCIPN). The FDA has designated KRN5500 as a Fast Track
Drug, and has granted DARA Orphan Drug Designation for the treatment of painful,
chronic chemotherapy-induced peripheral neuropathy that is refractory to
conventional analgesics (CCIPN). 


In early 2014, DARA kicked off its new partnership with Alamo Pharma Services, a
subsidiary of Mission Pharmacal, in deploying a dedicated 20-person national
sales team in the U.S. oncology market. In addition to promoting DARA's products
Soltamox, Gelclair and Bionect, this specialized oncology supportive care sales
team also provides clinicians with access to three Mission Pharmacal products:
Ferralet® 90 (for anemia), BINOSTO® (alendronate sodium effervescent tablet
indicated for the treatment of osteoporosis), and Aquoral® (for
chemotherapy/radiation therapy-induced dry mouth). 


Important Safety Information and full Prescribing Information for Mission
Pharmacal's products may be found at: www.Ferralet.com, www.Binosto.com, and
www.Aquoral.com.  


For more information please visit our web site at www.darabio.com. 

Forward-Looking Statements 

All statements in this press release that are not historical are forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995, and are subject to risks and uncertainties. Forward-looking statements are
based on the current expectations, estimates, forecasts and projections
regarding management's beliefs and assumptions. In some cases, you can identify
forward looking statements by terminology such as "may," "will," "should,"
"hope," "expects," "intends," "plans," "anticipates," "contemplates,"
"believes," "estimates," "predicts," "projects," "potential," "continue," and
other similar terminology or the negatives of those terms. Such forward-looking
statements are subject to factors that could cause actual results to differ
materially for DARA from those projected. Important factors that could cause
actual results to differ materially from the expectations described in these
forward-looking statements are set forth under the caption "Risk Factors" in
DARA's most recent Annual Report on Form 10-K, filed with the SEC on February 4,
2014, and DARA's other filings with the SEC from time to time. Those factors
include risks and uncertainties relating to DARA's ability to timely
commercialize and generate revenues or profits from Soltamox, Gelclair, Bionect
or other products given that DARA only recently hired its initial sales force
and DARA's lack of history as a revenue-generating company, DARA's ability to
achieve the desired results from the agreements with Mission and Alamo, FDA and
other regulatory risks relating to DARA's ability to market Soltamox, Gelclair,
Bionect or other products in the United States or elsewhere, DARA's ability to
in-license and/or partner products, DARA's current cash position and its need to
raise additional capital in order to be able to continue to fund its operations,
DARA's ability to raise sufficient capital and on favorable terms and the
stockholder dilution that may result therefrom, the current regulatory
environment in which DARA sells its products, the market acceptance of those
products, dependence on partners, successful performance under collaborative and
other commercial agreements, competition, the strength of DARA's intellectual
property and the intellectual property of others, the potential delisting of
DARA's common stock from the NASDAQ Capital Market, and other risk factors
identified in the documents DARA has filed, or will file, with the Securities
and Exchange Commission ("SEC"). Copies of DARA's filings with the SEC may be
obtained from the SEC Internet site at http://www.sec.gov. 


All forward-looking statements are expressly qualified in their entirety by this
cautionary notice. You are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this release. We
have no obligation, and expressly disclaim any obligation, to update, revise or
correct any of the forward-looking statements, whether as a result of new
information, future events or otherwise.



FOR FURTHER INFORMATION PLEASE CONTACT: 

Media Contact: 
David Connolly
LaVoieHealthSciences
617-374-8800, Ext. 108
[e-mail]

Corporate Contact:
Jim Polson
FTI Consulting
312 553 6730
[e-mail]